申请人:Research Foundation for the STATE UNIVERSITY OF NEW YORK
公开号:US20210311050A1
公开(公告)日:2021-10-07
The present disclosure is directed to methods of treating a disease associated with pathogenic B cells comprising administering to a subject in need thereof an effective amount of an Adora2A (adenosine A2A receptor) agonist. The method more specifically comprises: (a) obtaining a biological sample from a subject, wherein the sample comprises B cells; (b) detecting in the sample the presence of pathogenic B cells; (c) administering to the subject a pharmaceutically effective dose of an Adora2A receptor agonist (A2aR agonist) if pathogenic B cells are detected in step (b). The method may further comprise administering to the subject subsequent doses of a pharmaceutically effective dose of the A2aR agonist until pathogenic B cells are no longer detected.